@article{APS9835,
author = {Xi-nuo LI and Tai RAO and Yang-fan XU and Kang-rui HU and Zhang-pei ZHU and Hao-feng LI and Dian KANG and Yu-hao SHAO and Bo-yu SHEN and Xiao-xi YIN and Lin XIE and Guang-ji WANG and Yan LIANG},
title = {Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury},
journal = {Acta Pharmacologica Sinica},
volume = {39},
number = {8},
year = {2018},
keywords = {},
abstract = {Among the somatostatin analogues, octreotide (OCT) is the most commonly used in clinic via intravenous or subcutaneous injection to treat various diseases caused by increased secretion of growth hormone, gastrin or insulin. In order to assesse the feasibility of developing oral formulations of OCT, we conducted systematical pharmacokinetic and pharmacodynamic analyses of OCT in several animal models. The pharmacokinetic studies in rats showed that intragastric administration of OCT had extremely low bioavailability (},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/9835}
}